Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Geriatrics
Published in: BMC Geriatrics 1/2023

Open Access 01-12-2023 | Sarcopenia | Study Protocol

Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia—Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT): protocol of a cross-sequential study to explore the gut-muscle axis in the development and treatment of sarcopenia in community-dwelling older adults

Authors: Laurence Lapauw, Jolan Dupont, Nadjia Amini, Laura Vercauteren, Sabine Verschueren, Jos Tournoy, Jeroen Raes, Evelien Gielen

Published in: BMC Geriatrics | Issue 1/2023

Login to get access

Abstract

Background

Gut microbiota (GM) might play a role in muscle metabolism and physiological processes through a hypothesized gut-muscle axis, influencing muscle mass and function and thus, sarcopenia. The Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia—Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT) aims to explore the gut-muscle axis in sarcopenia.

Methods

First, in a cross-sectional case–control phase, 100 community-dwelling adults without sarcopenia will be compared to 100 community-dwelling adults (≥ 65 years) with sarcopenia of similar age-, gender and BMI-ratio, participating in the ongoing ‘Exercise and Nutrition for Healthy AgeiNg’ (ENHANce; NCT03649698) study. Sarcopenia is diagnosed according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. GM composition and intestinal inflammatory markers (fecal calprotectin, lactoferrin and S100A12) will be determined in fecal samples. Systemic inflammatory markers (hs-CRP, IL-4, IL-6, TNF-α, IL-13, IL-1β and creatine kinase) will be determined in fasted blood samples. Both groups will be compared using appropriate statistical testing, whereas linear regression will be used for cross-sectional associations between gut, inflammatory and sarcopenia parameters.
Second, in the longitudinal phase, sarcopenic older adults will be requested to deliver five fecal samples during the 12-week intervention to assess the effects of protein, omega-3 and a physical exercise program on the GM.

Discussion

TEMPUS-FUGIT aims to explore the gut-muscle axis by comparing GM composition between sarcopenic and non-sarcopenic older adults and to determine the association of GM with intestinal and systemic inflammatory markers and sarcopenia-defining parameters (muscle mass, muscle strength and physical performance). Furthermore, effects of single or combined, optimized and individualized anabolic interventions (exercise, protein and omega-3 supplementation), on GM will be explored in persons with sarcopenia.
TEMPUS-FUGIT aims to impact clinical practice by clarifying the relationship between the gut-muscle axis and sarcopenia. TEMPUS-FUGIT is expected to contribute to the discovery of clinical and microbial biomarkers for sarcopenia and insights in its pathophysiology, opening possible future perspectives for novel sarcopenia treatment strategies targeting GM.

Trial registration

ClinicalTrails.gov NCT05008770, registered on August 17, 2021; first participant enrolled on September 21 2021.
Appendix
Available only for authorised users
Literature
1.
Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle. 2019;10(5):956–61.PubMedPubMedCentral
2.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the european working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.PubMedPubMedCentral
3.
Chatzipetrou V, Bégin MJ, Hars M, Trombetti A. Sarcopenia in chronic kidney disease: a scoping review of prevalence, risk factors, association with outcomes, and treatment. Calcif Tissue Int. 2022;110(1):1–31.PubMed
4.
Li Cwei YuK, Shyh-Chang N, Jiang Z, Liu T, Ma S, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle. 2022;13(2):781–94.
5.
Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–46.PubMed
6.
Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86–99.PubMed
7.
von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010 12. 2010;1(2):129–33.
8.
Goates S, Du K, Arensberg M, Gaillard T, Guralnik J, Pereira S. Economic impact of hospitalizations in US adults with sarcopenia. J frailty aging. 2019;8(2):93–9.PubMed
9.
Pinedo-Villanueva R, Westbury L, Syddall H, Sanchez-Santos M, Dennison E, Robinson S, et al. Health care costs associated with muscle weakness: a UK population-based estimate. Calcif Tissue Int. 2019;104(2):137–44.PubMed
10.
Barone M, D’Amico F, Rampelli S, Brigidi P, Turroni S. Age-related diseases, therapies and gut microbiome: a new frontier for healthy aging. Mech Ageing Dev. 2022;1(206):111711.
11.
Bosco N, Noti M. The aging gut microbiome and its impact on host immunity. Genes Immun 2021 225. 2021;22(5):289–303.
12.
Ticinesi A, Lauretani F, Milani C, Nouvenne A, Tana C, Del Rio D, et al. Aging gut microbiota at the cross-road between nutrition, physical frailty, and sarcopenia: is there a gut-muscle axis? Nutrients. 2017;9(12):1303.PubMedPubMedCentral
13.
Biagi E, Rampelli S, Turroni S, Quercia S, Candela M, Brigidi P. The gut microbiota of centenarians: signatures of longevity in the gut microbiota profile. Mech Ageing Dev. 2017;165(Pt B):180–4.PubMed
14.
Costea PI, Hildebrand F, Manimozhiyan A, Bäckhed F, Blaser MJ, Bushman FD, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol. 2018;3(1):8–16.PubMed
15.
Ticinesi A, Tana C, Nouvenne A. The intestinal microbiome and its relevance for functionality in older persons. Curr Opin Clin Nutr Metab Care. 2019;22(1):4–12.PubMed
16.
Han DS, Wu WK, Liu PY, Yang YT, Hsu HC, Kuo CH, et al. Differences in the gut microbiome and reduced fecal butyrate in elders with low skeletal muscle mass. Clin Nutr. 2022;41(7):1491–500.PubMed
17.
Wang Y, Zhang Y, Lane NE, Wu J, Yang T, Li J, et al. Population-based metagenomics analysis reveals altered gut microbiome in sarcopenia: data from the Xiangya Sarcopenia Study. J Cachexia Sarcopenia Muscle. 2022;13(5):2340.PubMedPubMedCentral
18.
Kang L, Li P, Wang D, Wang T, Hao D, Qu X. Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia. Sci Reports 2021 111. 2021;11(1):1–14.
19.
Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;1:64.
20.
Wang T. Searching for the link between inflammaging and sarcopenia. Ageing Res Rev. 2022;1:77.
21.
Clemente JC, Manasson J, Scher JU. The role of the gut microbiome in systemic inflammatory disease. BMJ. 2018;360:j5145.PubMedPubMedCentral
22.
Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D. Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2019;25(1):67–73.PubMed
23.
Frank DN, Amand SA, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007;104(34):13780–5.PubMedPubMedCentral
24.
Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis. 2013;31(3–4):336–44.PubMed
25.
Carvalho A, Lu J, Francis JD, Moore RE, Haley KP, Doster RS, et al. S100A12 in digestive diseases and health: a scoping review. Gastroenterol Res Pract. 2020;2020:2868373.PubMedPubMedCentral
26.
Moreno-Pérez D, Bressa C, Bailén M, Hamed-Bousdar S, Naclerio F, Carmona M, et al. Effect of a protein supplement on the gut microbiota of endurance athletes: a randomized, controlled, double-blind pilot study. Nutrients. 2018;10(3):337.PubMedPubMedCentral
27.
Karl JP, Margolis LM, Madslien EH, Murphy NE, Castellani JW, Gundersen Y, et al. Changes in intestinal microbiota composition and metabolism coincide with increased intestinal permeability in young adults under prolonged physiological stress. Am J Physiol Gastrointest Liver Physiol. 2017;312(6):G559–71.PubMed
28.
Zhao X, Zhang Z, Hu B, Huang W, Yuan C, Zou L. Response of Gut Microbiota to Metabolite Changes Induced by Endurance Exercise. Front Microbiol. 2018;9(APR):765.PubMedPubMedCentral
29.
Dedeyne L, Dupont J, Koppo K, Verschueren S, Tournoy J, Gielen E. Exercise and Nutrition for Healthy AgeiNg (ENHANce) project - effects and mechanisms of action of combined anabolic interventions to improve physical functioning in sarcopenic older adults: study protocol of a triple blinded, randomized controlled trial. BMC Geriatr. 2020;20(1):532.PubMedPubMedCentral
30.
Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Vol. 48, Age and Ageing. Oxford University Press; 2019. p. 16–31.
31.
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.PubMedPubMedCentral
32.
Sousa-Santos AR, Amaral TF. Differences in handgrip strength protocols to identify sarcopenia and frailty - a systematic review. BMC Geriatr. 2017;17(1):238.PubMedPubMedCentral
33.
Roberts H, Denison H, Martin H, Patel H, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9.PubMed
34.
35.
Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc. 2013;14(8):542–59.PubMed
36.
Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–4.PubMed
37.
38.
39.
Baggen RJ, Van Roie E, Verschueren SM, Van Driessche S, Coudyzer W, van Dieën JH, et al. Bench stepping with incremental heights improves muscle volume, strength and functional performance in older women. Exp Gerontol. 2019;1(120):6–14.
40.
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94.PubMed
41.
Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the balance evaluation systems test: the mini-BESTest. J Rehabil Med. 2010;42(4):323–31.PubMed
42.
Collin C, Wade DT, Davies S, Horne V. The barthel ADL index: a reliability study. Int Disabil Stud. 1988;10(2):61–3.PubMed
43.
Aaronson NK, Muller M, Cohen PDA, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51(11):1055–68.PubMed
44.
Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing. 2015;44(6):960–6.PubMedPubMedCentral
45.
Yardley L, Beyer N, Hauer K, Kempen G, Piot-Ziegler C, Todd C. Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing. 2005;34(6):614–9.PubMed
46.
Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–9.PubMed
47.
Reitan R, Reitan R. Trail Making Test: Manual for Administration and Scoring. 1992;
48.
Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643–62.
49.
Huhmann MB, Perez V, Alexander DD, Thomas DR. A self-completed nutrition screening tool for community-dwelling older adults with high reliability: a comparison study. J Nutr Heal Aging. 2013;17(4):339–44.
50.
Smith K, Stevens R. Does a 10-week course of Otago exercises delivered in an NHS outpatient setting improve frailty, sarcopenia, and balance? Physiotherapy. 2021;1(113):e56–7.
51.
Liu-Ambrose T, Donaldson MG, Ahamed Y, Graf P, Cook WL, Close J, et al. Otago home-based strength and balance retraining improves executive functioning in older fallers: a randomized controlled trial. J Am Geriatr Soc. 2008;56(10):1821–30.PubMed
52.
Arumugam M, Raes J, Pelletier E, Le PD, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174–80.PubMedPubMedCentral
53.
Vandeputte D, De Commer L, Tito RY, Kathagen G, Sabino J, Vermeire S, et al. Temporal variability in quantitative human gut microbiome profiles and implications for clinical research. Nat Commun. 2021;12(1):6740.PubMedPubMedCentral
54.
Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, Mcglinn D, et al. Package “vegan” Title Community Ecology Package Version 2.5–7. 2020.
55.
Holmes I, Harris K, Quince C. Dirichlet multinomial mixtures: generative models for microbial metagenomics. PLoS ONE. 2012;7(2):e30126.PubMedPubMedCentral
56.
Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560–4.PubMed
57.
Xiao J, Cao H, Chen J. False discovery rate control incorporating phylogenetic tree increases detection power in microbiome-wide multiple testing. Bioinformatics. 2017;33(18):2873–81.PubMed
58.
Dedeyne L, Dupont J, Verschueren S, Koppo K, Tournoy J, Matthys C, et al. Personalized Protein Supplementation Improves Total Protein, Leucine, and Energy Intake in (Pre)Sarcopenic Community-Dwelling Older Adults in the ENHANce RCT. Front Nutr | www.​frontiersin.​org. 2021;1:672971.
59.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.PubMedPubMedCentral
60.
Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, et al. Intestinal Microbiota Is Influenced by Gender and Body Mass Index. PLoS ONE. 2016;11(5):e0154090.PubMedPubMedCentral
61.
Hu J, Zhong X, Liu Y, Yan J, Zhou D, Qin D, et al. Correlation between intestinal flora disruption and protein-energy wasting in patients with end-stage renal disease. BMC Nephrol. 2022;23(1):1–2.
62.
Akashi K, Yokoyama Y, Mizuno T, Abe T, Fukaya M, Asahara T, et al. Association between preoperative muscle mass and intraoperative bacterial translocation in patients undergoing hepatectomy, pancreatoduodenectomy, and esophagectomy. Ann Surg Oncol. 2019;26(13):4805–13.PubMed
63.
Zhang X, Zhao Y, Chen S, Shao H. Anti-diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications. J Cachexia Sarcopenia Muscle. 2021;12(6):1368–79.PubMedPubMedCentral
64.
Pero-Gascon R, Hemeryck LY, Poma G, Falony G, Nawrot TS, Raes J, et al. FLEXiGUT: Rationale for exposomics associations with chronic low-grade gut inflammation. Environ Int. 2022;1:158.
65.
Drabińska N, Jarocka-Cyrta E, Markiewicz LH, Krupa-Kozak U. The effect of oligofructose-enriched inulin on faecal bacterial counts and microbiota-associated characteristics in celiac disease children following a gluten-free diet: results of a randomized placebo-controlled trial. Nutr. 2018;10:201.
66.
Almutairi R, Basson AR, Wearsh P, Cominelli F, Rodriguez-Palacios A. Validity of food additive maltodextrin as placebo and effects on human gut physiology: systematic review of placebo-controlled clinical trials. Eur J Nutr 2022 616. 2022;61(6):2853–71.
67.
Picca A, Ponziani FR, Calvani R, Marini F, Biancolillo A, Coelho-Junior HJ, et al. Gut microbial, inflammatory and metabolic signatures in older people with physical frailty and sarcopenia: results from the BIOSPHERE study. Nutrients. 2020;12(1):65.
68.
Picca A, Ponziani FR, Calvani R, Marini F, Biancolillo A, Coelho-Júnior HJ, et al. Gut microbial, inflammatory and metabolic signatures in older people with physical frailty and sarcopenia: results from the BIOSPHERE study. Nutr 2020. 2019;12(1):65.
69.
Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nat. 2012;488(7410):178–84.
70.
Si J, Vázquez-Castellanos JF, Gregory AC, Decommer L, Rymenans L, Proost S, et al. Long-term life history predicts current gut microbiome in a population-based cohort study. Nat aging. 2022;2(10):885–95.PubMedPubMedCentral
Metadata
Title
Trial in Elderly with Musculoskeletal Problems due to Underlying Sarcopenia—Faeces to Unravel the Gut and Inflammation Translationally (TEMPUS-FUGIT): protocol of a cross-sequential study to explore the gut-muscle axis in the development and treatment of sarcopenia in community-dwelling older adults
Authors
Laurence Lapauw
Jolan Dupont
Nadjia Amini
Laura Vercauteren
Sabine Verschueren
Jos Tournoy
Jeroen Raes
Evelien Gielen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2023
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-023-04291-5

Other articles of this Issue 1/2023

BMC Geriatrics 1/2023 Go to the issue

Research

Associations between various types of activity and physical frailty in older Japanese: a cross-sectional study

Research

Research on layout model and construction planning of aged care institutions for disabled elders in China: based on Nanjing city data

Research

What makes a multidisciplinary medication review and deprescribing intervention for older people work well in primary care? A realist review and synthesis

Study Protocol

Self-management of geriatric syndromes - an observational study

Study Protocol

Exercise effects on functional capacity and quality of life in older patients with colorectal cancer: study protocol for the ECOOL randomized controlled trial

Research article

Association between handgrip strength and depression among Chinese older adults: a cross-sectional study from the China Health and Retirement Longitudinal Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits